Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial

BACKGROUND: SARS-CoV-2, the virus that causes COVID-19, enters the cells through a mechanism dependent on its binding to angiotensin-converting enzyme 2 (ACE2), a protein highly expressed in the lungs. The putative viral-induced inhibition of ACE2 could result in the defective degradation of bradyki...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansour, Eli, Bueno, Flávia F., de Lima-Júnior, José C., Palma, Andre, Monfort-Pires, Milena, Bombassaro, Bruna, Araujo, Eliana P., Bernardes, Ana Flavia, Ulaf, Raisa G., Nunes, Thyago A., Ribeiro, Luciana C., Falcão, Antônio Luís E., Santos, Thiago Martins, Trabasso, Plinio, Dertkigil, Rachel P., Dertkigil, Sergio S., Maia, Rafael P., Benaglia, Tatiana, Moretti, Maria Luiza, Velloso, Licio A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816150/
https://www.ncbi.nlm.nih.gov/pubmed/33472675
http://dx.doi.org/10.1186/s13063-021-05027-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816150/
https://www.ncbi.nlm.nih.gov/pubmed/33472675
http://dx.doi.org/10.1186/s13063-021-05027-9

Ejemplares similares